MS

Results from a key Canadian study into venoplasty for MS appear to have been prematurely released, leaving questions

The stem cell treatment for MS greeted as a “cure” is a breakthrough for five per cent of people with MS. What about the other 95 per cent?

Anne Kingston on how the criticism levelled at Kirsty Duncan over a controversial MS treatment is surprisingly unscientific

Two new studies suggest a potential game-changer in how scientists understand of the brain, which could advance research on MS and Alzheimer’s

Last week’s shut-down of the Albany, NY clinical trial investigating CCSVI treatment due to lack of patient enrollment is a big set-back on a number of fronts. It’s bad news for the Saskatchewan government, which allocated $2.2 million and recruited patients to travel to the U.S.—and a  blow for those who’d taken part in the trial or were lined up to go. But, like all failures, it’s instructive.

Anne Kingston explains why we’ve reached the WTF moment in CCSVI research

Patients are left with costs as discredited MS therapy circles the drain, writes Colby Cosh

MS drugs get fast-tracked all the time. Why can’t a clinical trial get the same treatment?

Zamboni’s research almost certainly has to have been junk

The Canadian military heads for the far North while Manitobans stare at a massive bill for flood cleanup.

Private member’s bill would see federal government fund clinical trials of controversial treatment

Experts and journalists are reading whatever they want into a new study examining CCSVI in MS patients